Krystal Biotech, Inc. - Common Stock (KRYS)
147.61
-2.39 (-1.59%)
NASDAQ · Last Trade: Jul 25th, 7:59 PM EDT
Via Benzinga · July 17, 2025
Via Benzinga · July 4, 2025
Via The Motley Fool · June 28, 2025

Via Benzinga · March 3, 2025
Via Benzinga · June 24, 2025
Via Benzinga · June 20, 2025
Via Benzinga · May 26, 2025
Via Benzinga · May 16, 2025
These 3 pharma stocks have oversold RSIs and solid analyst support, setting up potential bounce-back trades through this week and next
Via MarketBeat · May 14, 2025

Via Benzinga · February 24, 2025

Via Benzinga · February 20, 2025
Via Benzinga · May 9, 2025
Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.
Via Benzinga · April 30, 2025
Via Benzinga · April 28, 2025
Via Benzinga · April 28, 2025
Via Benzinga · April 14, 2025